Loading clinical trials...
Loading clinical trials...
A Phase 1, Multi-center, Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients Unresponsive to Standard Treatment With Pegylated Interferon and Ribavirin
First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.
First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125. Patients will proceed through a screening period, treatment period, and follow-up period of approximately 4 months' duration. There will be 4 dose cohorts including active drug and placebo dosing.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
University of Colorado Hospital
Aurora, Colorado, United States
Gastoenterstinal Specialist of Georgia, PA
Marietta, Georgia, United States
Henry Ford Med Ctr- Columbus
Novi, Michigan, United States
Duke University Medical Center
Durham, North Carolina, United States
The Liver Institute
Dallas, Texas, United States
Alamo Medical Research
San Antonio, Texas, United States
Fundacion de Investigacion de Diego
Santurce, Puerto Rico
Start Date
September 1, 2007
Primary Completion Date
December 1, 2009
Completion Date
May 1, 2010
Last Updated
February 15, 2019
58
ACTUAL participants
IMO-2125
DRUG
Saline placebo
DRUG
Lead Sponsor
Idera Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions